Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health VANCOUVER, British Columbia, July 28, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization (“CRO”), KGK Science Inc., (“KGK”) has recently achieved several milestones in its psychedelic research capabilities and significantly expanded its access to patients through…

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application Topshelf News.

source https://topshelf.news/ketamine-one-advances-research-capabilities-via-controlled-substance-dealers-licence-application/